Tue, 09 Sep 2014 19:00:00 GMT ~ Cellceutix Provides Initial Observations of Completed ABSSSI Phase 2b Trial; Company Submits Investigational New Drug Application to FDA for Phase 2 Trial of Brilacidin-OM for Oral Mucositis
[Marketwired] - Cellceutix Corporation , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, is pleased to announce this update on its recently ...
Fri, 05 Sep 2014 15:15:46 GMT ~ Cellceutix to Present at Rodman & Renshaw's 16th Annual Global Investment Conference
[Marketwired] - Cellceutix Corporation , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, announced today that Leo Ehrlich, CEO will be ...
Tue, 02 Sep 2014 11:00:00 GMT ~ Cellceutix Appoints Dr. Barry Schechter to Board of Directors as Company Focuses on Meeting Requirements for Stock Exchange Uplisting
[Marketwired] - Cellceutix Corporation , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, is pleased to announce the appointment of Dr. ...
Tue, 19 Aug 2014 12:30:00 GMT ~ Cellceutix Completes Enrollment in Phase 2b Clinical Trial of Brilacidin for Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
[Marketwired] - Cellceutix Corporation , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, has announced the completion of enrollment in ...
Business Description: An early stage developmental biopharmaceutical company...with six pharmaceutical compound candidates that are designed for treatment of diseases which may be either existing or diseases identified in the future. The Company will initially spend most of its efforts and resources on its anti-cancer compound, Kevetrin, for the treatment of head and neck cancers.
$CTIX share structure
## source: otcmarkets.com
Market Value: $225,776,700 a/o Sep 12, 2014 Shares Outstanding: 108,027,129 a/o May 07, 2014 Float: Not Available Authorized Shares: 300,000,000 a/o May 12, 2008
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.